Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis

OBJECTIVE: To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell lung cancer (NSCLC). METHODS: We systematically searched databases for randomized controlled trials on anlotinib treatment for patients with advanced NSCLC published until November 6,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Guocan, Shen, Yanqin, Xu, Xudong, Zhong, Fangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703897/
https://www.ncbi.nlm.nih.gov/pubmed/33253313
http://dx.doi.org/10.1371/journal.pone.0242982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703897/
https://www.ncbi.nlm.nih.gov/pubmed/33253313
http://dx.doi.org/10.1371/journal.pone.0242982

Ejemplares similares